Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...

INR:4858. deepak niwas kabaddi player Zhong Nanshan: We have just completed an experiment with sufficient evidence to prove that Lianhua Qingwen is ef ...